Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Advertisement
Yuanbin Chen, MD, PhDASCO 2024: Focus on Lung Cancer | July 18, 2024
The CheckMate 9LA study evaluated first-line nivolumab plus ipilimumab with 2 cycles of platinum-doublet chemotherapy.
View More
Ivania Valdés ArayaNon-Small Cell Lung Cancer | July 18, 2024
A researcher discusses the implications of identifying potentially pathogenic bacteria in adenocarcinoma tumors.
Katie KoskoNon-Small Cell Lung Cancer | July 17, 2024
The study showed that the detection of ctDNA predicted significantly inferior NSCLC.
Valsamo Anagnostou, MD, PhDNon-Small Cell Lung Cancer | July 17, 2024
Valsamo Anagnostou, MD, PhD, discusses advances in the field and her lab's research on the topic.
Cecilia BrownNon-Small Cell Lung Cancer | July 12, 2024
The drug combination showed "reduced efficacy" in terms of PFS and OS, officials said.
Cecilia BrownNon-Small Cell Lung Cancer | July 11, 2024
IDE397, a “potential first-in-class” MAT2A inhibitor, is under evaluation in phase 2 clinical trials.
Leah LawrenceNon-Small Cell Lung Cancer | July 12, 2024
Researchers compared outcomes between patients with baseline stage III N2 and non-N2 NSCLC.
Cecilia BrownNon-Small Cell Lung Cancer | July 9, 2024
The European Commission’s approval is based on results from the phase 3 FLAURA2 trial.
Katie KoskoASCO 2024: Focus on Lung Cancer | July 8, 2024
Most patients who received adjuvant osimertinib achieved MRD negativity.
Katie KoskoASCO 2024: Focus on Lung Cancer | July 4, 2024
Researchers assessed patients' functional health and well-being across multiple physical and mental domains.
Cecilia BrownNon-Small Cell Lung Cancer | June 27, 2024
The approval is based upon results from the phase 3 FLAURA2 trial and a subgroup analysis of a cohort from China.
Laila Gharzai, MDASCO 2024: Focus on Lung Cancer | June 27, 2024
Laila Gharzai, MD, discusses her research on the financial impacts of lung biomarker testing.
Minesh P. Mehta, MDLung Cancer | June 25, 2024
Dr. Mehta discusses the study, which met its primary end point, and future directions for the research.
Katie KoskoNon-Small Cell Lung Cancer | June 25, 2024
A prospective study evaluated if hypercoagulable and inflammatory biomarkers could predict certain outcomes.
Samantha Armstrong, MDASCO 2024: Focus on Lung Cancer | July 10, 2024
Samantha Armstrong, MD, and Karine Tawagi, MD, discuss the interview on the groundbreaking plenary presentation.
Leah LawrenceASCO 2024: Focus on Lung Cancer | June 24, 2024
An analysis of the phase 3 trial evaluated multiple aspects of health-related quality of life.
Katie KoskoASCO 2024: Focus on Lung Cancer | June 20, 2024
Certain patients appeared to derive the greatest benefit from the therapy.
Cecilia BrownNon-Small Cell Lung Cancer | June 18, 2024
The Biologics License Application is based upon data from the phase 3 PALOMA-3 study.
Nicolas Girard, MD, PhDASCO 2024: Focus on Lung Cancer | June 12, 2024
The phase 2 trial evaluated subcutaneous amivantamab and lazertinib as a first-line therapy for EGFR-mutated NSCLC.
Cecilia BrownLung Cancer | June 11, 2024
The supplemental New Drug Application is based on data from the phase 3 LAURA trial.
Advertisement
Advertisement
Advertisement
Latest News

July 18, 2024